Anti-inflammatory

Green Virgin Products' Moringa Oil Wins Award for Best Natural Beauty Product for 2024

Retrieved on: 
Wednesday, January 17, 2024

NEW YORK, Jan. 17, 2024 /PRNewswire/ -- HealthXWire has recognized Green Virgin Products' Moringa Oil, the all-natural, certified organic, non-toxic skin and hair care treatment, with the Best Natural Beauty Product for 2024 award.

Key Points: 
  • NEW YORK, Jan. 17, 2024 /PRNewswire/ -- HealthXWire has recognized Green Virgin Products' Moringa Oil, the all-natural, certified organic, non-toxic skin and hair care treatment, with the Best Natural Beauty Product for 2024 award.
  • Green Virgin Moringa Oil is extracted from the seeds of the moringa oleifera tree, found in tropical and subtropical countries around the world; its nutrient richness has helped the plant survive drought and harsh environmental conditions.
  • Green Virgin is proud to source its Moringa Oil exclusively from small organic growers.
  • The company's Moringa Oil is always 100% pure, extra virgin, cold-pressed, certified organic, and free of preservatives and chemicals.

Scinai Immunotherapeutics CEO Issues Letter to Shareholders

Retrieved on: 
Thursday, January 4, 2024

The Company will host a webinar on January 9th to expand on the content of the letter and invites you to submit questions both ahead of and during the webinar.

Key Points: 
  • The Company will host a webinar on January 9th to expand on the content of the letter and invites you to submit questions both ahead of and during the webinar.
  • The CEO letter reads as follows:
    Throughout 2023, I communicated my optimism about Scinai's future growth, including our potential to deliver value to our shareholders, stakeholders and partners.
  • Next, Scinai expects to commence toxicology studies which are required to receive regulatory approval to proceed with a first-in-human clinical trial, which Scinai expects to initiate early next year.
  • We expect Scinai Bioservices to grow and generate revenues in support of our NanoAb pipeline development.

Agomab Receives FDA Fast Track Designation for AGMB-129 in Fibrostenosing Crohn’s Disease and Starts STENOVA Phase 2a Clinical Trial

Retrieved on: 
Thursday, October 5, 2023

Agomab Therapeutics NV (‘Agomab’) today announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for AGMB-129 for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).

Key Points: 
  • Agomab Therapeutics NV (‘Agomab’) today announced that it received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for AGMB-129 for the potential treatment of Fibrostenosing Crohn’s Disease (FSCD).
  • In addition, Agomab has initiated its STENOVA Phase 2a clinical trial evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule inhibitor of ALK5 (TGF-βRI or ALK5), in patients with symptomatic FSCD.
  • AGMB-129 is the first drug candidate to receive FDA Fast Track Designation for the treatment of Fibrostenosing Crohn’s Disease.
  • The STENOVA Phase 2a clinical trial is a randomized, double-blind, placebo-controlled study in 36 patients with symptomatic FSCD.

Houston dermatologist develops new class of topical pain-relieving pharmaceuticals

Retrieved on: 
Friday, September 1, 2023

HOUSTON, Sep. 01, 2023 /PRNewswire/ -- Dr. Milton D. Moore, a leading dermatologist and founder & CEO of Moore Unique Skin Care, LLC and Moore Unique Dermatology, has introduced two new products under the brand name Moore Relief Dermaceuticals: Moore Relief Pain Discomfort Lotion and Moore Relief Skin Revitalizing & Burn Lotion. Initially formulated as moisturizing treatments for eczema and other conditions that cause skin irritation. Moore Relief Pain Discomfort Lotion and Moore Relief Skin Revitalizing & Burn Lotion are fast-acting, effective therapies that help relieve neuropathic skin discomfort, and helps heal burn wounds.

Key Points: 
  • The products will launch and be available for purchase with an amazing launch special price reduction of 51% on www.moorerelief.com on Thursday, August 31, 2023.
  • HOUSTON, Sep. 01, 2023 /PRNewswire/ -- Dr. Milton D. Moore, a leading dermatologist and founder & CEO of Moore Unique Skin Care, LLC and Moore Unique Dermatology , has introduced two new products under the brand name Moore Relief Dermaceuticals: Moore Relief Pain Discomfort Lotion and Moore Relief Skin Revitalizing & Burn Lotion.
  • Moore Relief Pain Discomfort Lotion and Moore Relief Skin Revitalizing & Burn Lotion are fast-acting, effective therapies that help relieve neuropathic skin discomfort, and helps heal burn wounds.
  • Each ingredient provides a unique contribution to the effectiveness of the products by cooling, moisturizing, and repairing damaged skin areas.

Phil and Teva Pharmaceuticals Launch New Program to Improve Access to the Digihaler® Family of Inhalers to Support Asthma Management

Retrieved on: 
Tuesday, June 6, 2023

The goal of Phil and Teva Pharmaceuticals’ partnership is to help enable patients to receive and refill their Digihaler medication quickly, easily and affordably.

Key Points: 
  • The goal of Phil and Teva Pharmaceuticals’ partnership is to help enable patients to receive and refill their Digihaler medication quickly, easily and affordably.
  • Using the PhilRx Patient Access Platform, patients can fill their prescription, review prescription records and obtain assistance navigating insurance benefits.
  • The PhilRx Patient Access Platform provides end-to-end visibility into the entire prescription life cycle, starting when the physician writes the prescription.
  • Physicians can select the PhilRx Patient Access Platform directly from an electronic medical record (EMR) to submit a prescription for a Digihaler product.

Gilad&Gilad Announcing a New Patent for Agmatine Treatment of Osteoarthritis

Retrieved on: 
Tuesday, May 2, 2023

GEORGETOWN, Texas, May 2, 2023 /PRNewswire-PRWeb/ -- The new patent, number: US 11,622,949 B1 (issued on April 11, 2023), is an extremely significant landmark achievement for Gilad&Gilad. It grants the company a unique market position by providing exclusive rights to tell users that agmatine and agmatine-containing compositions, which contain effective high amounts of the neuroprotective ingredient agmatine, known to support resilient neve activities, can also afford healthy joint functions.

Key Points: 
  • It is, therefore, timely and of cardinal importance that the United States Patent and Trademark Office (USPTO) has allowed Gilad&Gilad a new patent titled "Agmatine Compositions for treatment of Osteoarthritis".
  • GEORGETOWN, Texas, May 2, 2023 /PRNewswire-PRWeb/ -- The new patent, number: US 11,622,949 B1 (issued on April 11, 2023), is an extremely significant landmark achievement for Gilad&Gilad .
  • And importantly, agmatine exerts its salutary effects without causing unwanted side effects and it is not addictive."
  • The company has developed the exclusive Agmaceuticals(TM) line of products based on the breakthrough discovery of the neuroprotective properties agmatine.

Epione Medical Spa and Dr. Simon Ourian Announce New One-Hour, Non-Invasive Facelift

Retrieved on: 
Tuesday, November 29, 2022

Beverly Hills, California--(Newsfile Corp. - November 29, 2022) - Epione Medical Spa (Epione), which uses advanced lasers and stem cell/exosome technology to enhance each client's unique beauty and style, has begun offering its One-Hour Facelift.

Key Points: 
  • Beverly Hills, California--(Newsfile Corp. - November 29, 2022) - Epione Medical Spa (Epione), which uses advanced lasers and stem cell/exosome technology to enhance each client's unique beauty and style, has begun offering its One-Hour Facelift.
  • The procedure, created by Epione's founder and leading cosmetic dermatologist Dr. Simon Ourian , is incisionless and typically results in only a week's downtime.
  • Epione states that the One-Hour Facelift draws upon Dr. Simon's patented Coolaser technology as well as stem cell injections.
  • Dr. Simon Ourian is the founder of Epione Beverly Hills, the world's most advanced laser and aesthetic treatment center.

GLO24K Introduces its New and Improved Timeless Anti-Aging 24K Gold Mask. A Revolutionary 24K Gold SPA-Like Treatment to Nourish and Recharge the Skin.

Retrieved on: 
Tuesday, November 15, 2022

ATLANTA, Nov. 15, 2022 /PRNewswire/ -- GLO24K, an exclusive, trendy skincare brand based on 24k Gold has just launched its second generation of its 24K Anti-Aging Nourishing Gold Mask.

Key Points: 
  • ATLANTA, Nov. 15, 2022 /PRNewswire/ -- GLO24K, an exclusive, trendy skincare brand based on 24k Gold has just launched its second generation of its 24K Anti-Aging Nourishing Gold Mask.
  • The new and improved formula has all the benefits of the original 24K Gold Mask with new improvements in its potency, texture, and effectiveness.
  • The old Egyptians recognized the anti-aging benefits of 24K Gold and treated their royalty with 24K Gold Beauty Masks to keep their skin radiant and youthful.
  • Today, celebrities and supermodelshave integrated 24k Gold facials into their daily beauty routines and rave about it on social media.

Essex Biotechnology Secures Exclusive Global Rights and Interests of SkQ1 in the field Ophthalmology from Mitotech

Retrieved on: 
Thursday, October 13, 2022

Mitotech S.A. is a clinical-stage Luxembourg-based biotechnology company developing novel drugs for the treatment of predominantly age-related disorders.

Key Points: 
  • Mitotech S.A. is a clinical-stage Luxembourg-based biotechnology company developing novel drugs for the treatment of predominantly age-related disorders.
  • The core technology behind Mitotech products is based on a novel class of small molecules - mitochondria targeting cardiolipin peroxidation inhibitors.
  • Company's lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.
  • Additionally, glaucoma, Leber's Hereditary Optic Neuropathy (LHON), dry AMD, and uveitis programmes for SkQ1 ophthalmic solution are at pre-clinical stage.

SEPTEMBER IS NATIONAL CHRONIC PAIN MONTH AND THE OPIOID CRISIS IS IN FULL BLOOM. HOUSTON DERMATOLOGIST AND PHARMACIST HAS DEVELOPED A GROUNDBREAKING NEW CLASS OF TOPICAL PHARMACEUTICALS FOR PAIN THAT WILL NOT ADD TO THE CRISIS!

Retrieved on: 
Wednesday, September 28, 2022

HOUSTON, Sept. 28, 2022 /PRNewswire/ -- Dr. Milton D. Moore, a leading dermatologist and founder & CEO of Moore Unique Skin Care, LLC and Moore Unique Dermatology, today announced a new innovative product under the brand name Moore Relief Dermaceuticals: Moore Relief Pain Discomfort Lotion.

Key Points: 
  • The products have been launched and are available for purchase on www.moorerelief.com and Amazon.com.
  • The findings of Dr. Moore's clinical research in the development of this product were published in a recent article in the Journal ofDermatology Research (peer reviewed).
  • These products use Dr. Moore's patented transdermal delivery system, which enables the active ingredients to be absorbed by the skin quickly.
  • Dr. Milton Moore a pharmacist and dermatologist specializes in all types of dermatological products for 25 years.